Relay Therapeutics, Inc. (RLAY) FY2025 10-K Annual Report
Relay Therapeutics, Inc. (RLAY) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 26, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Relay Therapeutics, Inc. FY2025 10-K Analysis
Management Discussion & Analysis
- • Revenue $15.4M in 2025, up $5.3M YoY from $10.0M in 2024, primarily from Elevar Agreement milestones
- • Net loss $276.5M in 2025 vs $337.7M in 2024; operating expenses down to $318.1M from $382.5M; R&D $261.4M vs $319.1M, G&A $56.7M vs $76.6M
- • Best performing segment: License revenue from Elevar Agreement $15.4M in 2025; worst: Research & Development with $261.4M expense in 2025
- • Cash, cash equivalents, investments $554.5M as of Dec 31, 2025; raised $218.2M net in Sept 2024 offering; no share sales under $250M ATM facility; no disclosed dividends or buybacks
- • Management expects significant continued operating losses; cash runway into 2029; key risks include clinical trial progress, capital raising, regulatory approvals, and geopolitical/economic uncertainties
Risk Factors
- • FDA clinical holds risk, with trials subject to suspension due to safety concerns or regulatory noncompliance impacting lead candidate development
- • Enrollment delays from competition with other therapies and limited eligible patients constrain trial timelines and regulatory approvals
- • Dependence on third-party CROs and diagnostic partners, which may fail to meet contractual or regulatory requirements, delaying trials and companion diagnostics approval
- • Competition for patient enrollment from other oncology trials, including Pfizer’s selective-CDK4 inhibitor in metastatic breast cancer combination study
- • High operational risk from novel mechanism drug candidates requiring extensive R&D and potential unknown adverse effects raising development costs and regulatory hurdles
Relay Therapeutics, Inc. FY2025 Key Financial MetricsXBRL
Revenue
$15M
▲ +53.4% YoY
Net Income
-$276M
▲ +18.1% YoY
Operating Margin
-1971.6%
▲ +175048bp YoY
Net Margin
-1800.6%
▲ +157414bp YoY
ROE
-48.8%
▼ -534bp YoY
Total Assets
$621M
▼ -28.7% YoY
EPS (Diluted)
$-1.61
▲ +31.8% YoY
Operating Cash Flow
-$235M
▲ +5.5% YoY
Source: XBRL data from Relay Therapeutics, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Relay Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.